BIM
NVCR icon

Bogle Investment Management’s NovoCure NVCR Stock Holding History

Bogle Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,600
Closed -$401K – 226
2020
Q3 		$401K Buy
+3,600
New +$288K 0.12% 177
2019
Q4 		– Sell
-59,024
Closed -$4.41M – 300
2019
Q3 		$4.41M Buy
59,024
+7,200
+14% +$576K 0.38% 89
2019
Q2 		$3.28M Buy
+51,824
New +$2.63M 0.26% 117
2018
Q3 		– Sell
-80,423
Closed -$2.52M – 313
2018
Q2 		$2.52M Sell
80,423
-58,197
-42% -$1.62M 0.18% 134
2018
Q1 		$3.02M Buy
+138,620
New +$2.98M 0.23% 119

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bogle Investment Management's NVCR Position: Q4 2020 in Review

Bogle Investment Management sold out of NovoCure (NVCR) in Q4 2020, closing a stake of 3,600 shares — an estimated $401K sold.

Bogle Investment Management first reported a position in NVCR in Q1 2018 and held it in 5 quarters. The position peaked at $4.41M in Q3 2019. 357 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

  • Bogle Investment Management reported no remaining NovoCure position as of Q4 2020 after selling out during the quarter.
  • Bogle Investment Management sold 3,600 NovoCure shares in Q4 2020, an estimated $401K.
  • Bogle Investment Management first reported a position in NovoCure in Q1 2018 and held it in 5 quarters.
  • Bogle Investment Management's NovoCure position peaked at $4.41M in Q3 2019.
  • 357 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Bogle Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.